<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00123123</url>
  </required_header>
  <id_info>
    <org_study_id>NIDCR-14685</org_study_id>
    <secondary_id>R01DE014685</secondary_id>
    <secondary_id>1R01-DE-14685-1A2</secondary_id>
    <nct_id>NCT00123123</nct_id>
  </id_info>
  <brief_title>Effect of Improved Oral Hygiene to Prevent Pneumonia in Hospitalized Patients</brief_title>
  <official_title>Oral Health and Ventilator-associated Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Dental and Craniofacial Research (NIDCR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>State University of New York at Buffalo</source>
  <brief_summary>
    <textblock>
      Recent studies have found that poor oral hygiene may foster the colonization of the
      oropharynx by potential respiratory pathogens in mechanically-ventilated (MV), intensive care
      unit (ICU) patients. Thus, improvements in oral hygiene in MV-ICU patients may prevent
      ventilator-associated pneumonia (VAP).

      The specific aims of this investigation are: 1) to organize the necessary infrastructure to
      develop and perform a pilot clinical trial to evaluate alternative oral hygiene procedures to
      prevent VAP; 2) to use this organization to perform a pilot clinical trial to determine if
      the use of oral topical chlorhexidine gluconate (CHX) will prevent dental plaque,
      oropharyngeal colonization by respiratory pathogens, and VAP in MV-ICU patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent studies have found that poor oral hygiene may foster the colonization of the
      oropharynx by potential respiratory pathogens in mechanically-ventilated (MV), intensive care
      unit (ICU) patients. Thus, improvements in oral hygiene in MV-ICU patients may prevent
      ventilator-associated pneumonia (VAP). The Specific Aims of this investigation are: 1) to
      organize the necessary infrastructure to develop and perform a pilot clinical trial to
      evaluate alternative oral hygiene procedures to prevent VAP; 2) to use this organization to
      perform a pilot clinical trial to determine if the use of oral topical chlorhexidine
      gluconate (CHX) will prevent dental plaque, oropharyngeal colonization by respiratory
      pathogens, and VAP in MV-ICU patients. This pilot longitudinal, double blind intervention
      study will consider the appropriate frequency of delivery of CHX to improve oral hygiene in
      MV-ICU patients. Preliminary data from these pilot studies will also allow accurate sample
      size calculations to be made for a large-scale multi-center clinical trial; and 3) to perform
      molecular epidemiological studies to identify and genetically type bacteria cultured from
      lower airway secretions of MV-ICU patients with or without VAP and compare them to isolates
      of the same species from their dental plaque.

      This pilot study will enable this multidisciplinary team of investigators to organize the
      infrastructure, patient recruitment and methodologic protocols, and data management and
      analysis procedures necessary to perform a multi-center, controlled clinical trial to assess
      the efficacy and generalizability of this intervention to improve oral hygiene in MV-ICU and
      prevent VAP.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Colonization of the Oral Cavity by Respiratory Pathogens (on Teeth/Denture/Buccal Mucosa) as Determined by Quantitative Cultures Expressed as Colony Forming Units (Cfu) Per ml (CFU/mL) of the Aerobic Cultivable Flora After 48 Hours</measure>
    <time_frame>Every 48 hours until discharge</time_frame>
    <description>Samples were diluted and plated on sheep's blood agar (to isolate S. aureus), and MacConkey agar (for isolation of Gram-negative bacilli) and incubated for 72 hours at 37°C in 5% carbon dioxide. Plates were assessed for growth for the following target bacteria: S. aureus, P. aeruginosa, Acinetobacter species, and enteric organisms (Klebsiella pneumoniae, Serratia marcescens, Enterobacter species, Proteus mirabilis, Escherichia coli). Results of quantitative cultures were expressed as colony forming units (cfu) per ml of sample.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Pulmonary Infection Score (CPIS) at 48 Hours</measure>
    <time_frame>48 hours</time_frame>
    <description>The CPIS score was calculated as follows: 1) Fever: 0 (36.5 to 38.4°C), 1 (38.5 to 39), 2 (&lt;36.0 OR &gt;39.0); 2) Leukocytosis: 0 (4000 to 11,000 white blood cells per mm3 of blood), 1 (11,000 to 17,000), 2 (&gt;17,000); 3) New infiltrate:
0 = None, 1 = Patchy, 2 = Localized; 4) Secretions: 0 = None to minimal, 1 = moderate, 2 = large amount; and 5) PaO2/ FiO2: 0 = more than 330 and 2 = less than 330. Total scores for the subscales can range from 0-10, with lower scores indicating better outcome.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">175</enrollment>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>Placebo (Vehicle Control)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Delivered Twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.12% chlorhexidine gluconate oral rinse</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delivered twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.12% chlorhexidine oral rinse</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delivered once a day, placebo once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chlorhexidine gluconate oral rinse (0.12%)</intervention_name>
    <description>chlorhexidine gluconate oral rinse</description>
    <arm_group_label>0.12% chlorhexidine gluconate oral rinse</arm_group_label>
    <arm_group_label>0.12% chlorhexidine oral rinse</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo (Vehicle Control)</arm_group_label>
    <arm_group_label>0.12% chlorhexidine oral rinse</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients included in this study will be those admitted to the trauma intensive care
             unit (TICU) of Erie County Medical Center (ECMC) hospital. All patients admitted to
             the TICU who are intubated and mechanically ventilated within 24-48 hours of admission
             will be eligible for study admission, with the exception of those demonstrating the
             following exclusion criteria: a) a witnessed aspiration (to eliminate patients with
             chemical pneumonitis); b) a confirmed diagnosis of post-obstructive pneumonia (e.g.
             advanced lung cancer); c) a known hypersensitivity to CHX; d) patients for whom
             consent can not be obtained; e) a diagnosed thrombocytopenia (platelet count less than
             40 and/or a INR above 2) or other coagulopathy; f) a do not intubate order; g)
             children under the age of 18 years; h) Pregnant women; i) Legal incarceration; j) If
             transferred from another ICU; k) Those with oral mucositis; l) Those with
             immunosuppression (either-HIV or drug induced [e.g. organ transplant patients or those
             on long term steroid therapy]); m) Patients re-admitted to the TICU

          -  Comatose and intubated patients will be included since they represent patients at
             greatest risk for respiratory infection.

        Exclusion Criteria:

          -  Patients for whom consent can not be obtained.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank A. Scannapieco, DMD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University at Buffalo, The State University of New York</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank A. Scannapieco, DMD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The State University of New York</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Buffalo, The State University of New York</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Scannapieco FA, Yu J, Raghavendran K, Vacanti A, Owens SI, Wood K, Mylotte JM. A randomized trial of chlorhexidine gluconate on oral bacterial pathogens in mechanically ventilated patients. Crit Care. 2009;13(4):R117. doi: 10.1186/cc7967. Epub 2009 Jul 15.</citation>
    <PMID>19765321</PMID>
  </results_reference>
  <results_reference>
    <citation>Heo SM, Haase EM, Lesse AJ, Gill SR, Scannapieco FA. Genetic relationships between respiratory pathogens isolated from dental plaque and bronchoalveolar lavage fluid from patients in the intensive care unit undergoing mechanical ventilation. Clin Infect Dis. 2008 Dec 15;47(12):1562-70. doi: 10.1086/593193.</citation>
    <PMID>18991508</PMID>
  </results_reference>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2005</study_first_submitted>
  <study_first_submitted_qc>July 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2005</study_first_posted>
  <results_first_submitted>August 12, 2010</results_first_submitted>
  <results_first_submitted_qc>August 12, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 9, 2010</results_first_posted>
  <last_update_submitted>August 12, 2010</last_update_submitted>
  <last_update_submitted_qc>August 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Frank A Scannapieco, DMD, Ph.D</name_title>
    <organization>University of Buffalo</organization>
  </responsible_party>
  <keyword>Ventilator-associated pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 1 March, 2004 until 30 November, 2007. Subjects were recruited from patients admitted to the ICU of the Erie County Medical Center (ECMC) who were mechanically ventilated. This ICU provides trauma, burn care, and rehabilitation and is an affiliated teaching facility for the State University of New York at Buffalo.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Vehicle control twice a day (oral rinse)</description>
        </group>
        <group group_id="P2">
          <title>Chlorhexidine/Placebo</title>
          <description>Chlorhexidine oral rinse 1 oz once a day/placebo oral rinse once a day</description>
        </group>
        <group group_id="P3">
          <title>Chlorhexidine</title>
          <description>chlorhexidine 1 oz oral rinse twice a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Vehicle control twice a day (oral rinse)</description>
        </group>
        <group group_id="B2">
          <title>Chlorhexidine/Placebo</title>
          <description>Chlorhexidine oral rinse 1 oz once a day/placebo oral rinse once a day</description>
        </group>
        <group group_id="B3">
          <title>Chlorhexidine</title>
          <description>chlorhexidine 1 oz oral rinse twice a day</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="59"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="58"/>
            <count group_id="B4" value="175"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.0" spread="22.5"/>
                    <measurement group_id="B2" value="44.8" spread="19.9"/>
                    <measurement group_id="B3" value="47.6" spread="19.1"/>
                    <measurement group_id="B4" value="48.0" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Colonization of the Oral Cavity by Respiratory Pathogens (on Teeth/Denture/Buccal Mucosa) as Determined by Quantitative Cultures Expressed as Colony Forming Units (Cfu) Per ml (CFU/mL) of the Aerobic Cultivable Flora After 48 Hours</title>
        <description>Samples were diluted and plated on sheep's blood agar (to isolate S. aureus), and MacConkey agar (for isolation of Gram-negative bacilli) and incubated for 72 hours at 37°C in 5% carbon dioxide. Plates were assessed for growth for the following target bacteria: S. aureus, P. aeruginosa, Acinetobacter species, and enteric organisms (Klebsiella pneumoniae, Serratia marcescens, Enterobacter species, Proteus mirabilis, Escherichia coli). Results of quantitative cultures were expressed as colony forming units (cfu) per ml of sample.</description>
        <time_frame>Every 48 hours until discharge</time_frame>
        <population>All tests were carried out using intent-to-treat analysis, with two-sided tests with a significance level of 0.05. Baseline comparisons between groups were made by analysis of variance (ANOVA) and/or the chi-squared test, as appropriate.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Vehicle control twice a day (oral rinse)</description>
          </group>
          <group group_id="O2">
            <title>Chlorhexidine/Placebo</title>
            <description>Chlorhexidine oral rinse 1 oz once a day/placebo oral rinse once a day</description>
          </group>
          <group group_id="O3">
            <title>Chlorhexidine</title>
            <description>chlorhexidine 1 oz oral rinse twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Colonization of the Oral Cavity by Respiratory Pathogens (on Teeth/Denture/Buccal Mucosa) as Determined by Quantitative Cultures Expressed as Colony Forming Units (Cfu) Per ml (CFU/mL) of the Aerobic Cultivable Flora After 48 Hours</title>
          <description>Samples were diluted and plated on sheep's blood agar (to isolate S. aureus), and MacConkey agar (for isolation of Gram-negative bacilli) and incubated for 72 hours at 37°C in 5% carbon dioxide. Plates were assessed for growth for the following target bacteria: S. aureus, P. aeruginosa, Acinetobacter species, and enteric organisms (Klebsiella pneumoniae, Serratia marcescens, Enterobacter species, Proteus mirabilis, Escherichia coli). Results of quantitative cultures were expressed as colony forming units (cfu) per ml of sample.</description>
          <population>All tests were carried out using intent-to-treat analysis, with two-sided tests with a significance level of 0.05. Baseline comparisons between groups were made by analysis of variance (ANOVA) and/or the chi-squared test, as appropriate.</population>
          <units>CFU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="2"/>
                    <measurement group_id="O2" value="7.1" spread="1.9"/>
                    <measurement group_id="O3" value="5.1" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A mixed effect model was used to compare overall treatment effects between groups for repeated measures data. The group comparison for each time point was performed using ANOVA.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6750</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Pulmonary Infection Score (CPIS) at 48 Hours</title>
        <description>The CPIS score was calculated as follows: 1) Fever: 0 (36.5 to 38.4°C), 1 (38.5 to 39), 2 (&lt;36.0 OR &gt;39.0); 2) Leukocytosis: 0 (4000 to 11,000 white blood cells per mm3 of blood), 1 (11,000 to 17,000), 2 (&gt;17,000); 3) New infiltrate:
0 = None, 1 = Patchy, 2 = Localized; 4) Secretions: 0 = None to minimal, 1 = moderate, 2 = large amount; and 5) PaO2/ FiO2: 0 = more than 330 and 2 = less than 330. Total scores for the subscales can range from 0-10, with lower scores indicating better outcome.</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Vehicle control twice a day (oral rinse)</description>
          </group>
          <group group_id="O2">
            <title>Chlorhexidine/Placebo</title>
            <description>Chlorhexidine oral rinse 1 oz once a day/placebo oral rinse once a day</description>
          </group>
          <group group_id="O3">
            <title>Chlorhexidine</title>
            <description>chlorhexidine 1 oz oral rinse twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Pulmonary Infection Score (CPIS) at 48 Hours</title>
          <description>The CPIS score was calculated as follows: 1) Fever: 0 (36.5 to 38.4°C), 1 (38.5 to 39), 2 (&lt;36.0 OR &gt;39.0); 2) Leukocytosis: 0 (4000 to 11,000 white blood cells per mm3 of blood), 1 (11,000 to 17,000), 2 (&gt;17,000); 3) New infiltrate:
0 = None, 1 = Patchy, 2 = Localized; 4) Secretions: 0 = None to minimal, 1 = moderate, 2 = large amount; and 5) PaO2/ FiO2: 0 = more than 330 and 2 = less than 330. Total scores for the subscales can range from 0-10, with lower scores indicating better outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="1"/>
                    <measurement group_id="O2" value="2.5" spread="0.9"/>
                    <measurement group_id="O3" value="2.4" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Patients were followed until discharge from the intensive care unit</time_frame>
      <desc>The numbers of participants at risk do not match numbers of participants provided in the participant flow module since some patients exited study before 48 hour assessment point.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Vehicle control twice a day (oral rinse)</description>
        </group>
        <group group_id="E2">
          <title>Chlorhexidine/Placebo</title>
          <description>Chlorhexidine oral rinse 1 oz once a day/placebo oral rinse once a day</description>
        </group>
        <group group_id="E3">
          <title>Chlorhexidine</title>
          <description>chlorhexidine 1 oz oral rinse twice a day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Frank A. Scannapieco</name_or_title>
      <organization>University at Buffalo</organization>
      <phone>716-829-3373</phone>
      <email>fas1@buffalo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

